You are here

  • Home
  • Archive
  • Volume 24, Issue 3
  • Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Article info

Article menu
Download PDFPDF
Uterine Cancer
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

Authors

  1. Address correspondence and reprint requests Maysa M. Abu-Khalaf, MBBS, Section of Medical Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, 300 George Street, Suite 120, New Haven, CT 06511. E-mail: maysa.abu-khalaf{at}yale.edu.

Citation

Acevedo-Gadea C, Santin AD, Higgins SA, et al
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
International Journal of Gynecologic Cancer 2014;24:528-533.

Publication history

  • Received September 13, 2013
  • Accepted December 8, 2013
  • First published March 1, 2014.
Online issue publication 
March 01, 2014

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2014 by IGCS and ESGO